Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Clin Med ; 11(3)2022 Jan 22.
Artigo em Inglês | MEDLINE | ID: mdl-35160004

RESUMO

BACKGROUND: An extensive body of research suggests that brain inflammation and oxidative stress are the underlying causes of Parkinson's disease (PD), for which no potent therapeutic approach exists to mitigate the degradation of dopamine neurons. Freshwater clams, an ancient health food of Chinese origin, have been documented to exhibit anti-inflammatory and antioxidant effects. We previously reported that freshwater clam extract (FCE) can attenuate astrocytic activation and subsequent proinflammatory cytokine production from substantia nigra in an MPTP-induced PD mouse model. This article provides insight into the potential mechanisms through which FCE regulates neuroinflammation in a glia model of injury. MATERIALS AND METHODS: In total, 1 µg/mL lipopolysaccharide (LPS) and 200 µM rotenone were conducted in primary glial cell cultures to mimic the respective neuroinflammation and oxidative stress during injury-induced glial cell reactivation, which is relevant to the pathological process of PD. RESULTS: FCE markedly reduced LPS-induced neuroinflammation by suppressing NO and TNF-α production and the expression of pro-inflammatory cytokines. In addition, FCE was effective at reducing rotenone-induced toxicity by diminishing ROS production, promoting antioxidant enzymes (SOD, catalase, and GPx) and minimizing the decline in glial-cell-secreted neurotrophic factors (GDNF, BDNF). These impacts ultimately led to a decrease in glial apoptosis. CONCLUSIONS: Evidence reveals that FCE is capable of stabilizing reactive glia, as demonstrated by reduced neuroinflammation, oxidative stress, the increased release of neurotrophic factors and the inhibition of apoptosis, which provides therapeutic insight into neurodegenerative diseases, including PD.

2.
PLoS One ; 15(5): e0233289, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32469899

RESUMO

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by two aggregates, namely, amyloid-ß (Aß) plaques and neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein (tau-p), which are released into the blood in a very small amount and cannot be easily detected. An increasing number of recent studies have suggested that S-glutathionylated glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is highly correlated with Aß in patients with AD and that S-glutathionylated GAPDH plays a role as a proapoptotic factor in AD. We found that S-glutathionylated GAPDH is abundant in the blood of AD patients, which is unusual because S-glutathionylated GAPDH cannot exist in the blood under normal conditions. The aim of this study was to further explore the correlation between the S-glutathionylated GAPDH levels in blood plasma and AD progression. As controls, we recruited 191 people without AD, which included 111 healthy individuals and 37 patients with depression and insomnia, in the psychosomatic clinic. Moreover, 47 patients with AD (aged 40-89 years) were recruited at the neurology clinic. The blood S-glutathionylated GAPDH levels in the AD patients were significantly (p < 0.001) higher (752.7 ± 301.7 ng/dL) than those in the controls (59.92 ± 122.4 ng/dL), irrespective of gender and age. For AD diagnosis, the criterion blood S-glutathionylated GAPDH level > 251.62 ng/dL exhibited 95.74% sensitivity and 92.67% specificity. In fact, the individuals aged 70-89 years, namely, 37 patients from the psychosomatic clinic and 42 healthy individuals, showed significant blood S-glutathionylated GAPDH levels (230.5 ± 79.3 and 8.05 ± 20.51 ng/dL, respectively). This finding might indicate neurodegenerative AD progression in psychosomatic patients and suggests that the degree of neuronal apoptosis during AD progression might be sensitively evaluated based on the level of S-glutathionylated GAPDH in blood.


Assuntos
Doença de Alzheimer/sangue , Doença de Alzheimer/patologia , Proteínas Sanguíneas/metabolismo , Glutationa/química , Gliceraldeído-3-Fosfato Desidrogenase (Fosforiladora)/sangue , Processamento de Proteína Pós-Traducional , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Progressão da Doença , Feminino , Seguimentos , Gliceraldeído-3-Fosfato Desidrogenase (Fosforiladora)/química , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico
3.
Neurosci Lett ; 642: 51-58, 2017 03 06.
Artigo em Inglês | MEDLINE | ID: mdl-28126590

RESUMO

Freshwater clams are a popular health food in Asia and are traditionally used to prevent hepatic inflammation. Freshwater clam extract (FCE) inhibits inflammatory responses in activated macrophages by reducing the activation of mitogen-activated protein kinase and nuclear factor kappa-light-chain-enhancer of activated B cells. In this study, we used a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP; a neurotoxin)-induced Parkinson's disease (PD) to demonstrate the protective effect of FCE on dopamine neurons in the substantia nigra pars compacta (SNpc). Locomotor behavior and tyrosine hydroxylase immunohistochemical staining indicated that FCE significantly inhibited MPTP-induced dopaminergic cell loss in the SNpc. Glial fibrillary acidic protein immunohistochemistry and quantitative polymerase chain reaction analysis revealed that astroglial activation and tumor necrosis factor alpha, inducible nitric oxide synthase, and interleukin 1 beta production were significantly inhibited by FCE. The expressions of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and nerve growth factor were markedly increased by FCE action against MPTP-induced toxicity. FCE showed a neuroprotective effect in a MPTP-induced PD model, which might be correlated with anti-inflammation and the stimulation of neurotrophic factors.


Assuntos
Neurônios Dopaminérgicos/efeitos dos fármacos , Intoxicação por MPTP/prevenção & controle , Fármacos Neuroprotetores/uso terapêutico , Substância Negra/efeitos dos fármacos , Animais , Bivalves , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/metabolismo , Corpo Estriado/patologia , Dopamina/metabolismo , Neurônios Dopaminérgicos/metabolismo , Neurônios Dopaminérgicos/patologia , Intoxicação por MPTP/metabolismo , Intoxicação por MPTP/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Atividade Motora/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Teste de Desempenho do Rota-Rod , Substância Negra/metabolismo , Substância Negra/patologia , Tirosina 3-Mono-Oxigenase/metabolismo
4.
J Cell Physiol ; 230(7): 1567-79, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25535911

RESUMO

The NLRP3 inflammasome is a caspase-1-containing multi-protein complex that controls the release of IL-1ß and plays important roles in the development of inflammatory disease. Here, we report that resveratrol, a polyphenolic compound naturally produced by plants, inhibits NLRP3 inflammasome-derived IL-1ß secretion and pyroptosis in macrophages. Resveratrol inhibits the activation step of the NLRP3 inflammasome by suppressing mitochondrial damage. Resveratrol also induces autophagy by activating p38, and macrophages treated with an autophagy inhibitor are resistant to the suppressive effects of resveratrol. In addition, resveratrol administration mitigates glomerular proliferation, glomerular sclerosis, and glomerular inflammation in a mouse model of progressive IgA nephropathy. These findings were associated with decreased renal mononuclear leukocyte infiltration, reduced renal superoxide anion levels, and inhibited renal NLRP3 inflammasome activation. Our data indicate that resveratrol suppresses NLRP3 inflammasome activation by preserving mitochondrial integrity and by augmenting autophagy.


Assuntos
Proteínas de Transporte/metabolismo , Regulação da Expressão Gênica/fisiologia , Inflamação/metabolismo , Mitocôndrias/fisiologia , Estilbenos/farmacologia , Proteínas Adaptadoras de Transdução de Sinal/genética , Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Trifosfato de Adenosina/metabolismo , Animais , Proteínas Reguladoras de Apoptose/genética , Proteínas Reguladoras de Apoptose/metabolismo , Autofagia , Proteínas de Ligação ao Cálcio/genética , Proteínas de Ligação ao Cálcio/metabolismo , Proteínas de Transporte/genética , Caspase 1/genética , Caspase 1/metabolismo , Células Cultivadas , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Camundongos , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR , Fosforilação , Proteína Quinase C/metabolismo , Espécies Reativas de Oxigênio , Resveratrol
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...